摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3'',3'''-dichloro-4'',4'''-bis(m-carboxybenzyloxy)-5'',5'''-bis(m-carboxybenzyloxycarbonyl)-4',4'-diphenyl-3β-<1-(3'-butenyl)>cholestane tetramethyl ester

中文名称
——
中文别名
——
英文名称
3'',3'''-dichloro-4'',4'''-bis(m-carboxybenzyloxy)-5'',5'''-bis(m-carboxybenzyloxycarbonyl)-4',4'-diphenyl-3β-<1-(3'-butenyl)>cholestane tetramethyl ester
英文别名
(3-methoxycarbonylphenyl)methyl 3-chloro-5-[1-[3-chloro-4-[(3-methoxycarbonylphenyl)methoxy]-5-[(3-methoxycarbonylphenyl)methoxycarbonyl]phenyl]-4-[(3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]but-1-enyl]-2-[(3-methoxycarbonylphenyl)methoxy]benzoate
3'',3'''-dichloro-4'',4'''-bis(m-carboxybenzyloxy)-5'',5'''-bis(m-carboxybenzyloxycarbonyl)-4',4'-diphenyl-3β-<1-(3'-butenyl)>cholestane tetramethyl ester化学式
CAS
——
化学式
C81H92Cl2O14
mdl
——
分子量
1360.52
InChiKey
OTAVFLOMHJYVMA-DHSOJYCKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    22.1
  • 重原子数:
    97
  • 可旋转键数:
    32
  • 环数:
    10.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    176
  • 氢给体数:
    0
  • 氢受体数:
    14

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3'',3'''-dichloro-4'',4'''-bis(m-carboxybenzyloxy)-5'',5'''-bis(m-carboxybenzyloxycarbonyl)-4',4'-diphenyl-3β-<1-(3'-butenyl)>cholestane tetramethyl esterpotassium cyanidepotassium carbonate 作用下, 以 乙醇 为溶剂, 反应 10.0h, 以60%的产率得到3'',3'''-dichloro-4'',4'''-bis(m-carboxybenzyloxy)-5'',5'''-dicarboxy-4',4'-diphenyl-3β-<1-(3'-butenyl)>cholestane
    参考文献:
    名称:
    Extension of the Polyanionic Cosalane Pharmacophore as a Strategy for Increasing Anti-HIV Potency
    摘要:
    The anti-HIV agent cosalane inhibits both the binding of gp120 to CD4 as well as an undefined postattachment event prior to reverse transcription. Several cosalane analogues having an extended polyanionic "pharmacophore" were designed based on a hypothetical model of the binding of cosalane to CD4. The analogues were synthesized, and a number of them displayed anti-HIV activity. One of the new analogues was found to possess enhanced potency as an anti-HIV agent relative to cosalane itself. Although the new analogues inhibited both HIV-1 and HTV-2, they were more potent as inhibitors of HIV-1 than HIV-2. Mechanism of action studies indicated that the most potent of the new analogues inhibited fusion of the viral envelope with the cell membrane at lower concentrations than it inhibited attachment, suggesting inhibition of fusion as the primary mechanism of action.
    DOI:
    10.1021/jm980727m
  • 作为产物:
    描述:
    3-(溴甲基)苯甲酸甲酯铵5-[(Z)-1-(3-羧基-5-氯-4-羟基苯基)-4-[(3S,10S,13R,17R)-10,13-二甲基-17-(6-甲基庚烷-2-基)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-十四氢-1H-环戊二烯并[a]菲-3-基]丁-1-烯基]-3-氯-2-羟基苯甲酸酯potassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 16.0h, 以84%的产率得到3'',3'''-dichloro-4'',4'''-bis(m-carboxybenzyloxy)-5'',5'''-bis(m-carboxybenzyloxycarbonyl)-4',4'-diphenyl-3β-<1-(3'-butenyl)>cholestane tetramethyl ester
    参考文献:
    名称:
    Extension of the Polyanionic Cosalane Pharmacophore as a Strategy for Increasing Anti-HIV Potency
    摘要:
    The anti-HIV agent cosalane inhibits both the binding of gp120 to CD4 as well as an undefined postattachment event prior to reverse transcription. Several cosalane analogues having an extended polyanionic "pharmacophore" were designed based on a hypothetical model of the binding of cosalane to CD4. The analogues were synthesized, and a number of them displayed anti-HIV activity. One of the new analogues was found to possess enhanced potency as an anti-HIV agent relative to cosalane itself. Although the new analogues inhibited both HIV-1 and HTV-2, they were more potent as inhibitors of HIV-1 than HIV-2. Mechanism of action studies indicated that the most potent of the new analogues inhibited fusion of the viral envelope with the cell membrane at lower concentrations than it inhibited attachment, suggesting inhibition of fusion as the primary mechanism of action.
    DOI:
    10.1021/jm980727m
点击查看最新优质反应信息

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B